{
  "entities": {
    "activities": {
      "9d8a189c-99f5-4dda-9856-104c312b4027": "Apheresis",
      "6471826e-cb76-409a-8933-b6c2a4ed1061": "Blood Sampling",
      "ba264787-a5f4-4a0c-8563-40bb767601c0": "Chest Radiograph",
      "5b88e9fb-a7f6-4c2a-922a-779084248b98": "Clinical remission and not receiving concomitant corticosteroids at Week 44",
      "a251a49b-1023-4b88-9140-0a84b1ec215f": "Electrocardiogram",
      "097a2d46-5741-41ae-a4f6-6870e8ecd8eb": "Endoscopic healing at Week 44",
      "60ad06ed-2981-47ad-935d-5be2bdb7911b": "Endoscopy",
      "a86ad570-45d4-4fa0-972a-576c985df4dc": "Fecal Sample Collection",
      "b37d27c5-f85b-4c60-9c71-2d71ebc2f420": "Intravenous Infusion",
      "4e5280df-ff4e-4804-9362-b8a918411930": "Maintenance of clinical remission through Week 44 among the subjects who had achieved clinical remission at maintenance baseline (both global and US definitions)",
      "83ccb1e8-a586-4670-a3c0-872d0666606e": "Maintenance of clinical response through Week 44",
      "009fdaa1-ac7d-41da-b870-f774630a2a22": "Mucosal Biopsy",
      "01725ad9-4c0a-4978-9fd0-b56c4976c01b": "Physical Examination",
      "cdadf321-429a-43b5-81bf-ab12eef233af": "QuantiFERON-TB Gold Test",
      "5ab92a02-6a5d-46e4-87ef-49c44b6b9016": "Subcutaneous Injection",
      "2aead5a5-b379-46cf-9136-b323137893af": "Tuberculin Skin Test",
      "e581635d-a793-4a33-9787-c99066592462": "Vital Signs Monitoring"
    },
    "plannedTimepoints": {},
    "encounters": {
      "25c127df-ffb3-4bf5-ad91-aa9bebc76a14": "Placebo SC",
      "78946cd2-3ce8-45a4-a01b-f5249f5e1df7": "Ustekinumab 90 mg SC q12w",
      "267474ec-234f-420f-a47c-6bafd2d2fd22": "Ustekinumab 90 mg SC q8w"
    },
    "epochs": {
      "d92e306a-39d5-460b-855a-de82494d2505": "Maintenance Study"
    },
    "activityGroups": {}
  },
  "cells": {
    "83ccb1e8-a586-4670-a3c0-872d0666606e|25c127df-ffb3-4bf5-ad91-aa9bebc76a14": "both",
    "83ccb1e8-a586-4670-a3c0-872d0666606e|267474ec-234f-420f-a47c-6bafd2d2fd22": "both",
    "097a2d46-5741-41ae-a4f6-6870e8ecd8eb|25c127df-ffb3-4bf5-ad91-aa9bebc76a14": "both",
    "097a2d46-5741-41ae-a4f6-6870e8ecd8eb|267474ec-234f-420f-a47c-6bafd2d2fd22": "both",
    "5b88e9fb-a7f6-4c2a-922a-779084248b98|25c127df-ffb3-4bf5-ad91-aa9bebc76a14": "both",
    "5b88e9fb-a7f6-4c2a-922a-779084248b98|267474ec-234f-420f-a47c-6bafd2d2fd22": "both",
    "4e5280df-ff4e-4804-9362-b8a918411930|25c127df-ffb3-4bf5-ad91-aa9bebc76a14": "both",
    "4e5280df-ff4e-4804-9362-b8a918411930|267474ec-234f-420f-a47c-6bafd2d2fd22": "both"
  },
  "cellFootnotes": {
    "83ccb1e8-a586-4670-a3c0-872d0666606e|267474ec-234f-420f-a47c-6bafd2d2fd22": [
      "a"
    ],
    "097a2d46-5741-41ae-a4f6-6870e8ecd8eb|267474ec-234f-420f-a47c-6bafd2d2fd22": [
      "a"
    ],
    "5b88e9fb-a7f6-4c2a-922a-779084248b98|267474ec-234f-420f-a47c-6bafd2d2fd22": [
      "a"
    ],
    "4e5280df-ff4e-4804-9362-b8a918411930|25c127df-ffb3-4bf5-ad91-aa9bebc76a14": [
      "b"
    ],
    "4e5280df-ff4e-4804-9362-b8a918411930|267474ec-234f-420f-a47c-6bafd2d2fd22": [
      "a",
      "b"
    ]
  },
  "metadata": {
    "model": "gemini-3-flash-preview",
    "extraction_type": "text"
  }
}